| Prev Close: | 50.14 |
|---|---|
| Open: | 52.67 |
| Bid: | 52.26 x 600 |
| Ask: | 52.27 x 800 |
| 1y Target Est: | 60.16 |
| Beta: | 0.8 |
| Next Earnings Date: | 2-May-13 |
| Day's Range: | 51.95 - 53.21 |
|---|---|
| 52wk Range: | 24.12 - 55.16 |
| Volume: | 16,608,619 |
| Avg Vol (3m): | 11,116,300 |
| Market Cap: | 79.44B |
| P/E (ttm): | 31.82 |
| EPS (ttm): | 1.64 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
- Gilead Sciences' CEO Discusses Q1 2013 Results - Earnings Call TranscriptSeeking Alpha
- What Stocks to Sell – and Buy – in MayMichael Santoli
Headlines
- Radar Movers: Apple and AIG Climb Higher, LinkedIn Plunges 10%at Wall St. Cheat Sheet(Thu 9:46PM EDT)
- 3 Healthcare Stock Stories for Thursday Perusalat Wall St. Cheat Sheet(Thu 6:55PM EDT)
- [video] Lightning Roundat CNBC(Thu 6:40PM EDT)
- Gilead's HCV Drug Pipeline Outshines Weak Q1 Resultsat Investor's Business Daily(Thu 6:36PM EDT)
- UPDATE 2-Gilead profit rises, but sales of older HIV drugs dipat Reuters(Thu 6:28PM EDT)
- Final Glance: Biotechnology companiesAP(Thu 6:05PM EDT)
- Gilead Sciences 1Q income climbs 63 percentAP(Thu 6:03PM EDT)
- UPDATE 1-Gilead profit rises 63 pct, sales of older HIV drugs dipat Reuters(Thu 5:00PM EDT)
- Indexes End With Solid Gains; LinkedIn Slumps After Hoursat Investor's Business Daily(Thu 5:00PM EDT)
- Gilead Sciences Earnings: Here’s Why Shares are Down Nowat Wall St. Cheat Sheet(Thu 4:31PM EDT)
- Fifth & Pacific Companies Inc Earnings Call scheduled for 4:30 pm ET todayCCBN(Thu 4:30PM EDT)
- Gilead 1st-qtr profit rises 63 pct, sales of older HIV drugs dipat Reuters(Thu 4:25PM EDT)
- Gilead Misses Analysts’ Estimates on Sales of HIV Drugsat Bloomberg(Thu 4:22PM EDT)
- Gilead’s Hepatitis C Treatment Clears Virus in Eight Weeksat Bloomberg(Thu 4:21PM EDT)
- Wall Street closes up on tech gains, S&P near 1,600Reuters(Thu 4:17PM EDT)
Press Releases
- Gilead Sciences Announces First Quarter 2013 Financial ResultsBusiness Wire(Thu 4:05PM EDT)
- Gilead Reports Interim Data From Phase 2 LONESTAR StudyBusiness Wire(Thu 8:30AM EDT)
- Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and CobicistatBusiness Wire(Mon, Apr 29)
Reports
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(May 2)
- Wright Investors Service Comprehensive Report for Gilead Sciences, Inc.Wright Reports(May 1)
- Gilead SciencesS&P Capital IQ – STARS Reports(Apr 30)